In this issue:
Latitude and IBD risk
Rifaximin induces remission in CD
IBD increasing in developing and industrialised nations
Adalimumab achieves clinical remission in UC
Colectomy for UC: risk factors for postop complications
Maintenance of CD remission after infliximab withdrawal
Risk factors for chronic pouchitis
H1N1 vaccine: lower seroconversion in immunosuppressed IBD
Short, higher-dose infliximab infusions well tolerated
Immunosuppression and indeterminate QuantiFERON TB tests
Science blog: Helping IBD patients adhere to medical therapies
Please login below to download this issue (PDF)